Retatrutide Pen 40mg (4 x 10mg)
Research-grade retatrutide (LY3437943) triple GLP-1/GIP/glucagon agonist, pre-filled pen format, 40mg as 4 x 10mg. HPLC + MS verified, per-batch COA. Research use only.
| Purity (HPLC) | >=99% |
|---|---|
| Molecular weight | 4731.36 g/mol |
| CAS number | 2381089-83-2 |
| Synonyms | Retatrutide, LY3437943, Reta, Retatrutide pen, Triple-G agonist |
★ Bestseller
HPLC and MS verified by UKAS-accredited laboratories.
Royal Mail 24 and DPD Next Day options.
COA and batch number on every vial.
Retatrutide Pen 40mg (4 × 10mg) — research reference material
Retatrutide (development code LY3437943) is a synthetic, single-molecule triple agonist of the GLP-1, GIP and glucagon receptors, supplied by NMChem as a research reference material. This presentation is a pre-filled multi-dose pen containing 40 mg total, as 4 × 10 mg of retatrutide. It is supplied strictly for in-vitro laboratory research and is not for human or veterinary use.
Mechanism of research interest
Retatrutide is the most-studied of the “triple-G” incretin agonists. By engaging the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors simultaneously, it is investigated in metabolic-research contexts including incretin signalling, energy expenditure and lipid metabolism. See our retatrutide research reference for the full identifier graph and selected peer-reviewed literature, and peptides studied in metabolic research for class background.
Identifiers
- CAS number: 2381089-83-2
- Synonyms: Retatrutide, LY3437943, Reta
- Molecular weight: 4731.36 g/mol
- Class: GLP-1 / GIP / glucagon triple receptor agonist (peptide)
Format & quality
Supplied as a pre-filled pen (40 mg as 4 × 10 mg) in manufacturer packaging (Synedica), which includes disposable needles and an instruction booklet. Identity and purity are characterised by reversed-phase HPLC and mass spectrometry, with a per-batch Certificate of Analysis available on request. Compare retatrutide alongside other compounds on our comparison tool.
Storage
Store refrigerated and protected from light, per the batch Certificate of Analysis.
Research use only — not for human or veterinary use, food, cosmetic or therapeutic application. NMChem supplies this item as a laboratory reference material; no dosing or administration guidance is provided.
Frequently asked questions
What is retatrutide?
Retatrutide (LY3437943) is a synthetic peptide and the most-studied “triple-G” incretin agonist, acting on the GLP-1, GIP and glucagon receptors. NMChem supplies it as a research reference material only.
How does retatrutide differ from tirzepatide and semaglutide?
They differ in receptor coverage: semaglutide targets GLP-1, tirzepatide is a dual GLP-1/GIP agonist, and retatrutide is a triple GLP-1/GIP/glucagon agonist.
Is retatrutide legal in the UK?
Retatrutide is investigational and not licensed. It is supplied strictly as a research reference material, not for human use. See Are peptides legal in the UK? for the regulatory background.
What does the Retatrutide Pen 40mg contain?
40 mg of retatrutide as 4 × 10 mg in a pre-filled pen, in manufacturer packaging. Identity and purity are HPLC- and mass-spec-verified, with a per-batch Certificate of Analysis.
Reconstitution
For peptides supplied as lyophilised powder, reconstitute in bacteriostatic water or sterile saline at the concentration appropriate to your protocol. Allow the vial to come to room temperature before opening, add solvent slowly down the inside wall (do not directly onto the powder), and gently invert until clear. Do not vortex.
Reconstituted solutions are typically stable at 2–8°C for the durations published in the corresponding peer-reviewed reference. For long-term storage, aliquot and freeze at −20°C; avoid repeated freeze–thaw cycles.
You may also need
Related compounds
